A Multicenter, Double-Blind, Placebo-Controlled Study of 3 Doses of LY2140023 in Japanese Patients With DSM-IV-TR Schizophrenia.
Phase of Trial: Phase II
Latest Information Update: 20 May 2016
At a glance
- Drugs Pomaglumetad methionil (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 30 Aug 2012 Status changed from recruiting to discontinued, according to an Eli Lilly media release.
- 17 Nov 2011 Planned end date changed from 1 Jun 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
- 14 Oct 2010 Planned end date changed from 1 Feb 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.